Oral vs IV arsenic trioxide for standard-risk APL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is comparing an oral (pill) form of arsenic trioxide to the standard IV (drip) form. If you have already completed initial therapy for your type of leukemia and are in remission, this study could help you take your medicine as a pill instead of through a needle.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with a certain type of leukemia called APL (acute promyelocytic leukemia).
- Your white blood cell count at diagnosis must have been 10,000 or lower, which means you are considered standard-risk.
- You must have already completed your first therapy (called induction) with two drugs, arsenic trioxide (ATO) and ATRA, and achieved a complete remission (no signs of cancer).
- You must be in generally good health, with adequate liver, kidney, and heart function, and able to take care of yourself (ECOG performance status 0–2).
- You must be able to swallow oral medication without difficulty and have no serious stomach or bowel problems.
- You must not be pregnant or nursing, and if you could possibly have children, you must agree to use birth control.
- You must not have any other active cancer (with a few exceptions like fully treated skin cancer or certain in-situ cancers).
- You must not have active hepatitis B or C or HIV with a detectable viral load.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
This trial tests a drug called lisaftoclax to prevent differentiation syndrome, a serious complication that can occur during treatment of acute promyelocytic leukemia (APL). It aims to make treatment safer by reducing the risk of this side effect.
Hear when a new Acute Promyelocytic Leukemia With PML-RARA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.